Abstract:Abstract Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS), an overwhelming inflammatory condition, is characterized by systemic inflammation and multiorgan dysfunction. Neutrophil extrusion of neutrophil extracellular traps (NETs) and concomitant cell death process (NETosis) provides host defense, while neutrophil elastase (NE), a serine protease stored in the azurophilic granules of neutrophils, contributes to NETs for entrapping extracellular pathogens. Importantly, excess NETs and NETosis mediated pyroptosis in the etiopathogenesis. However, the exact mechanism underlying NE-mediated NET formation contributed to pyroptosis during ALI/ARDS remains unclear. In this study, we reported that neutrophils were susceptible to NETosis in the lungs of ARDS patients. We investigated the effects and the underlying mechanisms of an inhaled NE inhibitor AK0705 on lipopolysaccharide (LPS)-induced ALI in mice. The inflammatory cytokines assessments, pathologic examination, and detection of NETs indicated that inhalation of AK0705 ameliorated LPS-induced lung injury, and suppressed the secretion of IL-6, TNF-α, IL-1β, and MCP-1 in bronchoalveolar lavage fluid (BALF). Furthermore, the results of cell-free DNA, myeloperoxidase (MPO), citrullinated histone (citH3), NE level, and NE activity showed that AK0705 significantly inhibited LPS-induced NET formation. Western blot revealed that AK0705 effectively inhibited LPS-triggered pyroptosis by downregulating MAPK/AKT/NLRP3 signaling pathway. In conclusion, our investigation demonstrated for the first time that AK0705 could protect against LPS-induced ALI by promoting a reduction of NET formation and suppressing pyroptosis. These data suggest that targeting NETs, especially NE, using AK0705 is a promising approach to prevent NET formation in the progression of ALI/ALRDS.

Inhaled Neutrophil Elastase Inhibitor Alleviates Lipopolysaccharide Triggers Neutrophil Extracellular Trap-Mediated Acute Lung Injury via the MAPK/AKT/NLRP3 Pathway